Roivant Sciences Ltd.

ROIV · Healthcare

$34.52

Markedsværdi: 24.93B USDUdbytteafkast: —
AdvancedEr det et godt tidspunkt at købe Roivant Sciences Ltd.? Spørg Copenvest AIFå et Advanced AI-bud på timing, risiko og hvad tracked investorer gør.Spørg Copenvest AI

Indlæser diagram…

Nyheder

Seneste overskrifter for denne aktie

MarketBeat28. aug. 2026, 15.02

Roivant Sciences Wins FDA Approval for LISRAYA in Dermatomyositis, Launches Immediately

MT Newswires27. aug. 2026, 19.58

Roivant Sciences Gets FDA Approval for LISRAYA in Dermatomyositis; Shares Rise

GlobeNewswire27. aug. 2026, 19.29

Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.

GlobeNewswire27. aug. 2026, 19.28

Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.